loratadine has been researched along with Disorders of Excessive Somnolence in 3 studies
Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.
loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.
Disorders of Excessive Somnolence: Disorders characterized by hypersomnolence during normal waking hours that may impair cognitive functioning. Subtypes include primary hypersomnia disorders (e.g., IDIOPATHIC HYPERSOMNOLENCE; NARCOLEPSY; and KLEINE-LEVIN SYNDROME) and secondary hypersomnia disorders where excessive somnolence can be attributed to a known cause (e.g., drug affect, MENTAL DISORDERS, and SLEEP APNEA SYNDROME). (From J Neurol Sci 1998 Jan 8;153(2):192-202; Thorpy, Principles and Practice of Sleep Medicine, 2nd ed, p320)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Loratadine was significantly superior to placebo in 3 of 10 trials (30%), consistent with rates found in 3 pivotal group trials used for FDA approval (24%, 17%, and 0%)." | 2.70 | Single-patient drug trial methodology for allergic rhinitis. ( Del Rio, E; Rebell, G; Reitberg, DP; Weiss, SL; Zaias, N, 2002) |
| " Somnolence scores were similar for both groups at baseline and at the time of dosing (8:00 AM)." | 2.69 | Loratadine versus cetirizine: assessment of somnolence and motivation during the workday. ( Gates, D; Greiding, L; Heithoff, K; Ramon, F; Salmun, LM; Scharf, M, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reitberg, DP | 1 |
| Del Rio, E | 1 |
| Weiss, SL | 1 |
| Rebell, G | 1 |
| Zaias, N | 1 |
| Salmun, LM | 1 |
| Gates, D | 1 |
| Scharf, M | 1 |
| Greiding, L | 1 |
| Ramon, F | 1 |
| Heithoff, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prescription Methods Assessment Project (PMAP)[NCT00393653] | 800 participants (Anticipated) | Interventional | 2006-10-31 | Terminated (stopped due to Funding ended early) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for loratadine and Disorders of Excessive Somnolence
| Article | Year |
|---|---|
Single-patient drug trial methodology for allergic rhinitis.
Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Child; Chlorpheniramine; Clinical Trials as Topic; Da | 2002 |
Loratadine versus cetirizine: assessment of somnolence and motivation during the workday.
Topics: Adult; Anti-Allergic Agents; Cetirizine; Disorders of Excessive Somnolence; Double-Blind Method; Eff | 2000 |
1 other study available for loratadine and Disorders of Excessive Somnolence
| Article | Year |
|---|---|
Desloratadine (Clarinex).
Topics: Administration, Oral; Adolescent; Adult; Aged; Asthma; Controlled Clinical Trials as Topic; Disorder | 2002 |